Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis. PLoS Med. 2020;17: e1003501.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rahmah L, Abarikwu SO, Arero AG, Essouma M, Jibril AT, Fal A, Flisiak R, Makuku R, Marquez L, Mohamed K, Ndow L, Zarębska-Michaluk D, Rezaei N, Rzymski P. Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacol Rep. 2022;74:1255–78.

Article  PubMed  PubMed Central  CAS  Google Scholar 

https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (Accessed 15 July 2023)

Tian F, Chen Z, Feng Q. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2023;95: e28732.

Article  PubMed  CAS  Google Scholar 

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, non-hospitalized adults with COVID-19. N Engl J Med. 2022;386:1397–408.

Article  PubMed  CAS  Google Scholar 

Amstutz A, Speich B, Mentré F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023;11:453–64.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA, GS-US-540-9012 (PINETREE) Investigators. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022;386:305–15.

Article  PubMed  CAS  Google Scholar 

Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang M, Mao Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54:516–23.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zadeh F, Wilson D, Agrawal D. Long COVID: complications, underlying mechanisms, and treatment strategies. Arch Microbiol Immunol. 2023;7:36–61.

PubMed  PubMed Central  Google Scholar 

Fernández-de-las-Peñas C. Long COVID: current definition. Infection. 2022;50:285–6.

Article  PubMed  Google Scholar 

Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102–7.

Article  PubMed  CAS  Google Scholar 

Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604–15.

Article  PubMed Central  Google Scholar 

Rahmati M, Udeh R, Yon DK, Lee SW, Dolja-Gore X, McEVoy M, Kenna T, Jacob L, López Sánchez GF, Koyanagi A, Shin JI, Smith L. A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: a call to action for neurological, physical, and psychological sciences. J Med Virol. 2023;95: e28852.

Article  PubMed  CAS  Google Scholar 

Suran M. VA Finds nirmatrelvir associated with lower risk of long COVID. JAMA. 2022;328:2386.

PubMed  Google Scholar 

Peluso MJ, Anglin K, Durstenfeld MS, et al. Effect of oral nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies. Pathog Immun. 2022;7:95–103.

PubMed  PubMed Central  Google Scholar 

Sebők S, Gyires K. Long COVID and possible preventive options. Inflammopharmacology. 2023. https://doi.org/10.1007/s10787-023-01204-1.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n7.

Google Scholar 

Wells GA, Tugwell P, O’Connell D, Welch V, Peterson J, Shea B, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses 2015.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.

Article  PubMed  Google Scholar 

Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19. medRxiv 2022.11.03.22281783; https://doi.org/10.1101/2022.11.03.22281783

Boglione L, Meli G, Poletti F, Rostagno R, Moglia R, Cantone M, Esposito M, Scianguetta C, Domenicale B, Di Pasquale F, Borrè S. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022;114:865–71.

Article  PubMed  CAS  Google Scholar 

Badenes Bonet D, Caguana Vélez OA, Duran Jordà X, et al. Treatment of COVID-19 during the acute phase in hospitalized patients decreases post-acute sequelae of COVID-19. J Clin Med. 2023;12:4158.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nevalainen OPO, Horstia S, Laakkonen S, et al. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat Commun. 2022;13:6152.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183:554–64.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chuang MH, Wu JY, Liu TH, Hsu WH, Tsai YW, Huang PY, Lai CC. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J Med Virol. 2023;95: e28750.

Article  PubMed  CAS  Google Scholar 

Bramante CT, Buse JB, Liebovitz DM, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;S1473–3099:00299–302.

Google Scholar 

Milne A, Maskell S, Sharp C, Hamilton FW, Arnold DT. Impact of dexamethasone on persistent symptoms of COVID-19: an observational study. medRxiv; doi: https://doi.org/10.1101/2021.11.17.21266392

National Institute for Health and Care Excellence (NICE), Royal College of General Practitioners, Healthcare Improvement Scotland SIGN. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National institute for health and care excellence, 2020. www.nice.org.uk/ guidance/ng188 (accessed Oct 30, 2022).

Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, Van Eyck L, Pawlak S, Kadar EP, Clark F, Shi H, Anderson AS, Binks M, Menon S, Nucci G, Bergman A. Innovative Randomized phase i study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of Nirmatrelvir. Clin Pharmacol Ther. 2022;112:101–11.

Article  PubMed  CAS  Google Scholar 

Paxlovid EU. Accessed 15 July 2023. Available from: https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Paxlovid Pages/emergency-use-authorization.aspx

Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev. 2021;34:e00162-e220.

CAS  Google Scholar 

RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693–704.

Article  Google Scholar 

Lv Z, Guo Y. Metformin and its benefits for various diseases. Front Endocrinol. 2020;11:191.

Article  Google Scholar 

Fernández-de-las-Peñas C, Rodríguez-Jiménez J, Cancela-Cilleruelo I, Guerrero-Peral A, Martín-Guerrero JD, García-Azorín D, Cornejo-Mazzuchelli A, Hernández-Barrera V, Pellicer-Valero OJ. Post-COVID-19 symptoms 2 years after SARS-CoV-2 infection among hospitalized vs non-hospitalized patients. JAMA Netw Open. 2022;5: e2242106.

Article  PubMed  PubMed Central  Google Scholar 

Kuri-Ayache M, Rivera-Cavazos A, Pérez-Castillo MF, Santos-Macías JE, González-Cantú A, Luviano-García JA, Jaime-Villalón D, Gutierrez-González D, Romero-Ibarguengoitia ME. Viral load and its relationship with the inflammatory response and clinical outcomes in hospitalization of patients with COVID-19. Front Immunol. 2023;13:1060840.

Article  PubMed  PubMed Central  Google Scholar 

Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881–95.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19. N Engl J Med. 2022;387:599–610.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mulchandani R, Lyngdoh T, Kakkar AK. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. Eur J Clin Invest. 2021;51: e13429.

Article  PubMed  CAS  Google Scholar 

Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30:1–9.

Article  PubMed  CAS  Google Scholar 

Castle BT, Dock C, Hemmat M, Kline S, Tignanelli C, Rajasingham R, Masopust D, Provenzano P, Langlois R, Schacker T, Haase A, Odde DJ. Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets. bioRxiv 2020.05.22.111237

Tran VT, Riveros C, Clepier B, et al. Development and validation of the long COVID symptom and impact tools, a set of patient-reported instruments constructed